Tosaki T.,TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology |
Kamiya H.,Aichi Medical University |
Kato Y.,Aichi Medical University |
Kondo M.,Aichi Medical University |
And 8 more authors.
Journal of the Japan Diabetes Society | Year: 2015
This study was conducted to investigate the efficacy and safety of a SGLT2 inhibitor, ipragliflozin, in Japanese patients with type 2 diabetes. Ipragliflozin was administered to a total of 89 out-patients treated with or without other oral hypoglycemic agents, insulin, or GLP-1 receptor agonists for 12 weeks. Significant decreases were observed in the HbA1c value from 7.46 ± 1.12 % to 7.02 ± 0.99 % (p<0.001), body weight from 76.4 ± 14.4 kg to 74.5 ± 14.2 kg (p<0.001), visceral fat mass from 100.4 ± 39.5 cm2 to 93.2 ± 33.7 cm2 (p= 0.011), systolic and diastolic blood pressure, waist circumference and the EGFR. As adverse events of ipragliflozin treatment, whole body eruption, cystitis and vaginal candidiasis in one case and non-severe hypoglycemia in 2 cases were observed. Ipragliflozin is relatively well-tolerated and effective for the treatment of Japanese obese patients with type 2 diabetes.